At the news
? NEUTRALIMPACT 9/10 8-K filed Apr 23, 2026 at 08:54 ET
Day One Biopharmaceuticals (DAWN) was acquired by Servier Pharmaceuticals in an all-cash transaction valued at $2.5 billion, resulting in delisting from Nasdaq and termination of all existing equity plans. The merger closed after Servier secured 85.34% of shares in a tender offer.
- Servier Pharmaceuticals completed acquisition of Day One Biopharmaceuticals for $2.5 billion in equity value
- All outstanding shares converted to $21.50 in cash per share
- Company delisted from Nasdaq following merger completion
- Board and officers replaced with Servier appointees
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access